Cargando…

ALT-803 in the treatment of non-muscle-invasive bladder cancer: Preclinical and clinical evidence and translational potential

Bladder cancer (BCa) is one of the most common malignant tumors that cause death. Approximately 75%–85% of BCa develop into non-muscle-invasive bladder cancer (NMIBC). Bacillus Calmette-Guérin (BCG) is the gold standard for avoiding cystectomy in the treatment of NMIBC. Unfortunately, up to 30% of p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Wujun, Liu, Ning, Yuan, Yang, Zhu, Meng, Hu, Xiaokun, Hu, Wenchao, Wang, Shuai, Wang, Chao, Huang, Binghuan, Xing, Dongming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684637/ https://www.ncbi.nlm.nih.gov/pubmed/36439125 http://dx.doi.org/10.3389/fimmu.2022.1040669

Ejemplares similares

Intravesical ALT-803 for BCG-unresponsive Bladder Cancer – A Case Report
por: Huang, Jeffrey, et al.
Publicado: (2017)

Enhanced efficacy of ALT-803, an IL-15-based superagonist complex, in combination with immune checkpoint inhibitors in an orthotopic muscle invasive bladder tumor model in mice
por: Xu, Wenxin, et al.
Publicado: (2015)

Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model
por: Furuya, Hideki, et al.
Publicado: (2019)

CITN-06: a Phase I/expansion trial of alt-803, an IL-15 superagonist, in patients with advanced melanoma
por: Margolin, Kim, et al.
Publicado: (2014)

A novel signature constructed by differential genes of muscle-invasive and non-muscle-invasive bladder cancer for the prediction of prognosis in bladder cancer
por: Wang, Weizhuo, et al.
Publicado: (2023)

Intravesical ALT-803 and BCG Treatment Reduces Tumor Burden in a Carcinogen Induced Bladder Cancer Rat Model; a Role for Cytokine Production and NK Cell Expansion
por: Gomes-Giacoia, Evan, et al.
Publicado: (2014)

Association between ALT/AST and Muscle Mass in Patients with Type 2 Diabetes Mellitus
por: Ma, Wenjie, et al.
Publicado: (2022)

Oktett, D. 803
por: Schubert, Franz, 1797-1828
Publicado: (1988)

Enhanced efficacy of IL-15-based ALT-803 superagonist complex in combination with immune checkpoint inhibitors in hematologic and metastatic mouse tumor models
por: Xu, Wenxin, et al.
Publicado: (2014)

Schedule of experiment R803
por: Jarlskog, G
Publicado: (1973)

Oktett F-Dur, D. 803= octet in F major D 803
por: Schubert, Franz 1797-1828
Publicado: (2014)

The IL-15 superagonist ALT-803 enhances anti-CD20 antibody-directed NK cell ADCC and in vivo clearance of B cell lymphomas
por: Rosario, Maximillian, et al.
Publicado: (2014)

Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC
por: Basher, Fahmin, et al.
Publicado: (2015)

Study on liver histopathology of chronic HBV infected patients with different normal ALT values
por: Zeng, Zhan, et al.
Publicado: (2022)

New insights into bacterial mechanisms and potential intestinal epithelial cell therapeutic targets of inflammatory bowel disease
por: Liang, Bing, et al.
Publicado: (2022)

Characterization of the tumor-infiltrating immune repertoire in muscle invasive bladder cancer
por: Benítez, Raquel, et al.
Publicado: (2023)

The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8(+) T cells into innate-like effector cells with antitumor activity
por: Wong, Hing C, et al.
Publicado: (2013)

Combinatorial therapy with an IL-15 superagonist (ALT-803) and anti-PD-L1 mAb augment T cell mediated anti-tumor immunity in mice
por: Johnson, Christopher B, et al.
Publicado: (2014)

An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells
por: Fantini, Massimo, et al.
Publicado: (2019)

New insights into the suppression of inflammation and lipid accumulation by JAZF1
por: Chen, Wujun, et al.
Publicado: (2022)

Octets D. 803 , D. 72
por: Schubert, Franz, 1797-1828
Publicado: (1993)

The potential role and mechanism of circRNA/miRNA axis in cholesterol synthesis
por: Chen, Wujun, et al.
Publicado: (2023)

Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer
por: Chen, Hualin, et al.
Publicado: (2022)

Molecular, Immunological, and Clinical Features Associated With Lymphoid Neogenesis in Muscle Invasive Bladder Cancer
por: Pagliarulo, Fabio, et al.
Publicado: (2022)

Pyroptosis-Related Signature Predicts Prognosis and Immunotherapy Efficacy in Muscle-Invasive Bladder Cancer
por: Zhang, Qi, et al.
Publicado: (2022)

Real-world retrospective study of immune checkpoint inhibitors in combination with radiotherapy or chemoradiotherapy as a bladder-sparing treatment strategy for muscle-invasive bladder urothelial cancer
por: Xu, Chao, et al.
Publicado: (2023)

R803 at intersection I8, ISR
Publicado: (1975)

R803 at intersection I8, ISR
por: CERN PhotoLab
Publicado: (1975)

R803 at intersection I8, ISR
por: CERN PhotoLab
Publicado: (1975)

New Horizons for the Roles and Association of APE1/Ref-1 and ABCA1 in Atherosclerosis
por: Chen, Wujun, et al.
Publicado: (2021)

Erratum: Molecular, Immunological, and Clinical Features Associated With Lymphoid Neogenesis in Muscle Invasive Bladder Cancer
Publicado: (2022)

IL15N72D superagonist/IL15Rα-Fc fusion complex (ALT-803) exhibits anti-metastatic activity in murine breast tumor model
por: Kim, Peter S, et al.
Publicado: (2015)

Preoperative sarcopenia and systemic immune-inflammation index can predict response to intravesical Bacillus Calmette-Guerin instillation in patients with non-muscle invasive bladder cancer
por: Liu, Peng, et al.
Publicado: (2022)

A higher De Ritis ratio (AST/ALT) is a risk factor for progression in high-risk non-muscle invasive bladder cancer
por: Fukui-Kawaura, Sachi, et al.
Publicado: (2021)

A Muscle-Invasive Bladder Cancer Patient With High Tumor Mutational Burden and RB1 Mutation Achieved Bladder Preservation Following Chemotherapy Combined With Immunotherapy: A Case Report
por: Cao, Chuanzhen, et al.
Publicado: (2021)

A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer
por: Wu, Xiangkun, et al.
Publicado: (2020)

Development and external validation of a novel nomogram model for predicting postoperative recurrence-free survival in non-muscle-invasive bladder cancer
por: Ding, Li, et al.
Publicado: (2022)

803. Overcoming β-Lactam Resistance in Mycobacterium abscessus
por: Story-Roller, Elizabeth, et al.
Publicado: (2018)

IL-15 and N-803 for HIV Cure Approaches
por: Howard, J. Natalie, et al.
Publicado: (2023)

Alt a 1 Promotes Allergic Asthma In Vivo Through TLR4-Alveolar Macrophages
por: Hernandez-Ramirez, Guadalupe, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_viqer1nodv4vnbiivu0b2bhgm9